everi
step
viral
life
cycl
depend
host
potenti
explor
antivir
target
histor
howev
drug
discoveri
focus
mainli
viral
target
perceiv
specif
effort
pursu
host
target
larg
hamper
concern
potenti
ontarget
toxic
lack
predict
cell
cultur
anim
model
complex
hostviru
interact
hand
distinct
advantag
target
host
creat
high
barrier
resist
provid
broad
coverag
differ
genotypesserotyp
possibl
even
multipl
virus
expand
list
potenti
target
druggabl
viral
target
limit
take
hepat
c
viru
hcv
exampl
inhibitor
viral
proteas
polymeras
protein
current
advanc
clinic
test
howev
resist
becom
main
challeng
directact
antivir
hcv
rna
viru
notori
prone
mutat
singl
mutat
viral
target
may
prevent
bind
inhibitor
render
ineffect
host
cyclophilin
inhibitor
shown
promis
effect
vitro
patient
prevent
emerg
resist
cure
hcv
infect
either
alon
combin
agent
also
capabl
block
replic
number
viral
pathogen
road
develop
hosttarget
antivir
less
travel
signific
challeng
remain
deliv
effect
antivir
regimen
may
compris
inhibitor
host
viral
target
well
worth
effort
virus
particularli
small
genom
encod
protein
depend
host
mani
essenti
function
natur
select
therefor
favor
virus
effici
hijack
host
machineri
hepat
c
viru
hcv
prime
exampl
enter
cell
bind
cell
surfac
receptor
pileri
et
al
human
scaveng
receptor
class
b
type
scarselli
et
al
tight
junction
protein
evan
et
al
occludin
ploss
et
al
follow
decapsid
releas
positivestrand
rna
genom
viral
polyprotein
translat
intern
ribosom
entri
site
ire
recruit
number
cellular
protein
includ
eukaryot
initi
factor
hellen
pestova
polyprotein
subsequ
cleav
individu
viral
protein
host
signal
peptidas
peptid
peptidas
well
viral
proteas
et
al
replic
complex
form
viral
nonstructur
protein
cellular
cofactor
endoplasm
reticulum
er
deriv
membran
synthes
negativeand
positivestrand
viral
rna
romerobrey
et
al
virion
contain
positivestrand
viral
rna
genom
assembl
erassoci
lipid
droplet
ld
viral
core
protein
locat
bud
er
lumen
golgi
releas
lindenbach
summari
essenti
everi
step
hcv
life
cycl
depend
host
given
host
interact
critic
viral
replic
one
would
imagin
mani
host
factor
could
potenti
antivir
target
howev
antivir
drug
discoveri
histor
focus
mainli
viral
target
almost
current
approv
antivir
drug
exclud
immunomodul
develop
target
viral
protein
exampl
five
licens
hepat
b
viru
hbv
inhibitor
nucleo
ide
polymeras
inhibitor
fung
et
al
herpesviru
drug
target
viral
dna
polymeras
price
prichard
current
two
class
inhibitor
influenza
viral
neuraminidas
inhibitor
channel
blocker
barik
two
dozen
human
immunodefici
viru
drug
approv
target
viral
revers
transcriptas
proteas
integras
de
clercq
hosttarget
antivir
success
develop
maraviroc
inhibitor
block
entri
dorr
et
al
hepat
c
activ
area
antivir
drug
develop
past
two
decad
two
drug
alreadi
approv
inhibit
viral
proteas
mani
develop
target
viral
polymeras
protein
hand
resist
becom
main
challeng
directact
antivir
high
replic
mutat
rate
viru
altern
complementari
strategi
target
host
factor
essenti
viral
replic
may
creat
higher
genet
barrier
resist
could
use
combin
viral
inhibitor
review
discuss
opportun
challeng
develop
hosttarget
antivir
use
cyclophilin
inhibitor
specif
exampl
system
screen
ration
approach
employ
identifi
novel
host
factor
essenti
viral
replic
effort
taken
screen
cellular
protein
directli
interact
specif
protein
et
al
influenza
viru
sharma
et
al
hcv
taguwa
et
al
wang
et
al
huang
et
al
howev
method
yeasttwo
hybrid
screen
often
result
hit
necessarili
function
relev
thu
import
confirm
find
either
loss
eg
sirna
gain
eg
ectop
express
function
studi
common
approach
screen
host
sirna
librari
target
lead
inhibit
viral
replic
knock
multipl
screen
perform
brass
et
al
zhou
et
al
influenza
viru
et
al
hcv
li
et
al
tai
et
al
interestingli
percentag
overlap
hit
screen
done
differ
group
viru
surprisingli
low
could
result
either
differ
assay
condit
andor
high
rate
fals
posit
except
exampl
report
hit
almost
everi
hcv
screen
perform
use
either
subgenom
replicon
fulllength
infecti
viru
borawski
et
al
tai
et
al
berger
et
al
trotard
et
al
vaillancourt
et
al
reiss
et
al
reproduc
hit
suggest
target
less
like
affect
condit
cell
assay
may
thu
repres
attract
candid
drug
discoveri
whole
cellbas
phenotyp
screen
larg
compound
librari
also
gener
lot
lead
unknown
target
mechan
kim
et
al
chockalingam
et
al
gastaminza
et
al
compound
inhibit
viral
target
easili
rule
secondari
screen
remain
hit
could
candid
identifi
potenti
host
target
challeng
deconvolut
pathway
identifi
target
use
chemogenet
approach
pulldown
protein
target
use
label
inhibitor
advantag
approach
target
confirm
lead
compound
alreadi
identifi
potenti
chemistri
start
point
transcript
proteom
profil
compar
virusinfect
cell
uninfect
cell
drugtreat
vs
untreat
cell
could
also
gener
rich
inform
hostviru
interact
su
et
al
jacob
et
al
xu
et
al
sometim
target
pursu
base
specif
hypothesi
ribavirin
known
enhanc
antivir
respons
use
combin
exact
mechan
ribavirin
remain
unclear
weak
inhibitor
dehydrogenas
impdh
catalyz
convers
imp
xmp
essenti
step
de
novo
biosynthesi
guanin
nucleotid
inhibit
impdh
lead
deplet
intracellular
gtp
pool
thu
block
viral
replic
hypothesi
trigger
effort
develop
potent
specif
inhibitor
impdh
merimepodib
inde
block
hcv
replic
vitro
show
antivir
effect
patient
markland
et
al
marcellin
et
al
focus
approach
analyz
specif
pathway
known
involv
viral
replic
exampl
well
character
hcv
replic
erassoci
membran
web
structur
hcv
virion
assembl
erassoci
lipid
droplet
affect
host
lipid
biosynthesi
romerobrey
et
al
lindenbach
thu
cellular
protein
involv
lipid
metabol
could
potenti
antivir
target
sever
studi
demonstr
statin
abl
inhibit
hcv
replic
vitro
ikeda
et
al
kim
et
al
specif
inhibitor
diglycerid
report
block
hcv
virion
assembl
releas
herker
et
al
recent
fatti
acid
synthas
propos
anoth
host
antivir
target
evanchik
et
al
huang
et
al
pathway
involv
hcv
replic
potenti
host
target
known
inhibitor
summar
tabl
mani
host
factor
known
essenti
viral
replic
exploit
drug
develop
perceiv
hurdl
tabl
common
myth
host
target
specif
thu
may
caus
toxic
inhibit
normal
cellular
function
host
protein
could
potenti
lead
targetrel
toxic
mani
way
risk
mitig
first
rapidli
multipli
viru
like
differ
threshold
certain
protein
function
normal
cell
reflect
fact
mani
cellular
pathway
gene
upregul
infect
cell
therefor
possibl
knock
target
normal
level
may
suffici
block
viral
replic
maintain
cellular
function
second
often
redund
pathway
protein
given
cellular
function
inhibit
particular
target
uniqu
viru
could
compens
anoth
cellular
protein
overlap
function
third
mani
cellular
gene
actual
nonessenti
inhibit
may
toler
depend
concentr
durat
treatment
risk
targetrel
toxic
differ
type
drug
discoveri
object
remain
identifi
optim
dose
drug
achiev
desir
therapeut
effect
without
incur
signific
toxic
anoth
myth
host
target
often
mere
vitro
artifact
poor
translat
vivo
clinic
efficaci
mainli
function
host
target
like
affect
vitro
cell
cultur
condit
anim
model
employ
signific
differ
target
pathway
vitro
vivo
one
might
see
poor
correl
effect
exampl
impdh
inhibitor
potent
inhibit
hcv
replic
vitro
efficaci
patient
limit
variabl
mchutchison
et
al
rustgi
et
al
one
possibl
explan
level
suppli
nucleotid
thu
depend
viral
replic
de
novo
synthesi
differ
vitro
vivo
could
significantli
affect
efficaci
inhibitor
modul
nucleotid
metabol
also
true
compound
modul
pyrimidin
biosynthesi
dhodh
hoffmann
et
al
statin
anoth
exampl
show
strong
antihcv
activ
vitro
ikeda
et
al
gave
larg
disappoint
result
clinic
studi
bader
et
al
sezaki
et
al
ford
et
al
oleari
et
al
milazzo
et
al
probabl
antivir
effect
statin
significantli
affect
cellular
level
cholesterol
lipid
quit
differ
vitro
patient
therefor
inde
challeng
host
target
liabl
lack
predict
vitro
model
impact
host
polymorph
also
examin
mechan
action
hosttarget
inhibitor
usual
much
complex
difficult
determin
inhibitor
viral
target
hand
signific
advantag
pursu
host
target
especi
fact
host
target
could
provid
higher
barrier
resist
viral
inhibitor
take
hcv
exampl
despit
success
develop
specif
inhibitor
viral
target
resist
becom
major
challeng
hcv
rna
viru
notori
prone
mutat
resist
viral
rnadepend
rna
polymeras
proofread
function
result
high
error
rate
synthes
viral
rna
mutat
per
viral
genom
produc
powdril
et
al
combin
high
replic
rate
virion
per
day
hcv
exist
larg
pool
variant
quasispeci
everi
patient
ribeiro
et
al
theoret
mean
mutat
alreadi
preexist
start
antivir
treatment
moreov
viral
inhibitor
discov
date
singl
mutat
viral
gene
could
affect
inhibitor
bind
site
confer
high
level
resist
resist
therefor
develop
quickli
vitro
patient
complementari
arguabl
better
strategi
target
host
factor
creat
higher
genet
barrier
resist
hosttarget
inhibitor
also
help
cover
multipl
viral
genotyp
serotyp
sinc
host
factor
less
like
affect
viral
heterogen
furthermor
mani
virus
exploit
cellular
pathway
replic
perceiv
alreadi
demonstr
vitro
hosttarget
inhibitor
activ
multipl
virus
markland
et
al
pfefferl
et
al
concept
develop
broadspectrum
antivir
desir
probabl
necessari
situat
respiratori
infect
caus
clear
quick
diagnosi
avail
host
target
also
feasibl
approach
tackl
agent
polyomavirus
druggabl
viral
target
avail
limit
host
factor
involv
pathogenesi
viral
infect
also
explor
target
pastorino
et
al
mclay
et
al
anoth
potenti
advantag
host
target
mani
alreadi
investig
pursu
clinic
indic
thu
known
inhibitor
alreadi
avail
valid
target
case
provid
faster
develop
path
certainli
case
cyclophilin
inhibitor
discuss
interest
pursu
cyclophilin
potenti
target
hcv
trigger
unexpect
clinic
find
cyclosporin
csa
approv
immunosuppress
drug
prevent
graft
reject
follow
solid
organ
transplant
also
antiinflammatori
effect
use
treat
psoriasi
ulcer
coliti
clinic
trial
origin
design
investig
benefit
csa
suppress
hepatitisassoci
inflamm
surprisingli
discov
combin
csa
result
significantli
greater
antivir
respons
alon
inou
et
al
function
cyclophilin
hcv
replic
direct
antivir
activ
csa
confirm
vitro
watashi
et
al
nakagawa
et
al
knockdown
cyclophilin
replicon
cell
use
specif
sirna
also
led
strong
inhibit
hcv
replic
nakagawa
et
al
yang
et
al
gaither
et
al
cyclophilin
famili
highli
conserv
cellular
peptidylprolyl
cistran
isomeras
ppias
involv
mani
cellular
process
protein
fold
traffick
human
cyclophilin
differ
subcellular
local
function
wang
heitman
cyclophilin
cypa
first
identifi
handschumach
et
al
bind
partner
csa
block
tcell
activ
product
inhibit
calcineurin
nfat
although
ppias
function
cypa
involv
activ
zydowski
et
al
cypa
one
abund
cytosol
protein
protein
interestingli
essenti
cell
cypa
knockout
mice
gener
healthi
decreas
life
span
colgan
et
al
main
side
effect
allerg
blephar
observ
human
treat
cyclophilin
inhibitor
find
suggest
pharmacolog
inhibit
cyclophilin
may
well
toler
role
cyclophilin
hcv
replic
extens
studi
sinc
discoveri
ppias
function
cyclophilin
convert
prolin
protein
transto
cisform
requir
conform
traffick
mani
protein
andor
format
multiprotein
complex
function
essenti
hcv
replic
chatterji
et
al
liu
et
al
kaul
et
al
furthermor
domain
ii
hcv
protein
directli
interact
cyclophilin
substrat
cypa
cypb
ppias
vitro
hanoul
et
al
shown
model
illustr
fig
current
data
suggest
cyclophilin
inhibitor
block
viral
replic
mainli
disrupt
interact
cypa
viral
protein
thu
format
activ
replic
complex
hand
like
oversimplifi
model
data
suggest
cyclophilin
play
addit
role
hcv
life
cycl
shown
previous
cypb
also
bind
hcv
protein
directli
stimul
rna
synthesi
activ
vitro
watashi
et
al
heck
et
al
anoth
studi
suggest
cypa
recruit
hcv
replic
complex
via
interact
liu
et
al
cyclophilin
may
also
involv
hcv
polyprotein
process
specif
selfcleavag
junction
ciesek
et
al
cleavag
junction
proteas
kaul
et
al
moreov
inhibit
cyclophilin
may
alter
lipid
traffick
block
virion
secret
anderson
et
al
recent
report
treatment
cyclophilin
inhibitor
led
enhanc
secret
type
type
iii
ifn
increas
express
ifnstimul
gene
isg
vitro
patient
suggest
cyclophilin
inhibitor
help
restor
host
innat
immun
respons
hcv
infect
hopkin
et
al
summari
cyclophilin
probabl
involv
multipl
step
hcv
life
cycl
remain
elucid
although
csa
show
interest
clinic
efficaci
hcv
patient
obviou
concern
use
highli
immunosuppress
drug
treat
chronic
viral
infect
fortun
follow
discoveri
csa
number
analog
identifi
year
differ
properti
term
calcineurinbind
immunosuppress
antihcv
activ
csa
discov
old
compound
examin
activ
inhibit
hcv
vitro
antihcv
activ
cyclosporin
analog
shown
correl
cyclophilinbind
affin
calcineurinbind
immunosuppress
activ
et
al
nonimmunosuppress
cyclosporin
analog
methylisoleucin
posit
instead
methylleucin
csa
fig
emerg
ideal
candid
exhibit
higher
bind
affin
cyclophilin
csa
complet
devoid
calcineurinmedi
immunosuppress
activ
billich
et
al
inhibit
hcv
replic
vitro
ec
absenc
human
serum
presenc
human
serum
pharmacokinet
profil
quit
similar
csa
induc
signific
nephrotox
like
csa
probabl
attribut
calcineurin
inhibit
anoth
major
advantag
gener
larg
quantiti
total
biosynthesi
ie
ferment
use
genet
modifi
cyclosporinproduc
strain
weber
et
al
thu
provid
quick
develop
path
pharmacokinet
safeti
first
evalu
singl
ascend
dose
studi
healthi
volunt
compound
administ
oral
subject
divid
five
differ
dose
group
mg
well
toler
drugrel
advers
event
either
lab
result
clinic
evalu
compound
rapidli
absorb
peak
concentr
c
max
occur
blood
h
dose
termin
elimin
halflif
around
h
drug
exposur
increas
dose
slightli
underproport
compound
subsequ
investig
doubleblind
placebocontrol
studi
genotyp
hcvinfect
patient
multipl
ascend
dose
mg
daili
qd
mg
twice
daili
bid
given
oral
monotherapi
day
lawitz
et
al
signific
chang
c
max
slightli
higher
auc
day
vs
day
pharmacokinet
compar
hcvinfect
patient
healthi
subject
dose
well
toler
seriou
advers
event
common
side
effect
mild
moder
headach
drugtreat
group
vs
placebo
mild
clinic
nonsignific
elev
bilirubin
signific
declin
platelet
count
observ
mg
bid
group
interestingli
signific
reduct
alt
observ
dose
mg
bid
absenc
virolog
respons
suggest
benefici
biochem
respons
unrel
antivir
effect
compound
howev
signific
viral
load
reduct
observ
monotherapi
mg
bid
c
trough
compound
blood
still
well
serumadjust
hcv
replicon
ec
extrapol
ec
human
serum
thu
higher
dose
compound
would
like
requir
achiev
antivir
efficaci
howev
exposur
drug
alreadi
doseproport
ie
increas
mg
bid
mg
bid
mg
bid
mg
bid
increas
dose
use
formul
may
suffici
differ
strategi
therefor
consid
base
enhanc
antivir
effect
observ
vitro
combin
et
al
well
clinic
data
demonstr
csa
plu
effect
inou
et
al
rather
increas
dose
monotherapi
compound
investig
combin
twenti
genotyp
hcv
patient
relaps
prior
therapi
random
receiv
mg
bid
match
placebo
day
day
mean
reduct
hcv
viral
load
log
arm
compar
log
alon
arm
p
also
alt
decreas
ul
baselin
ul
day
combin
arm
wherea
unchang
ul
alon
arm
main
safeti
find
decreas
platelet
count
l
baselin
l
day
combin
arm
vs
l
control
arm
also
statist
clinic
signific
increas
serum
bilirubin
seriou
advers
event
observ
either
group
despit
promis
proofofconcept
efficaci
result
signific
challeng
develop
particularli
absenc
solid
formul
longterm
studi
dose
efficaci
compound
also
like
limit
underproport
exposur
signific
side
effect
decreas
platelet
alisporivir
potent
nonimmunosuppress
cyclosporin
analog
methylalanin
posit
instead
sarcosin
csa
nethyl
valin
posit
instead
nmethyl
leucin
fig
modif
abolish
calcineurin
bind
activ
also
increas
bind
affin
cyclophilin
paeshuys
et
al
thu
compound
potent
csa
inhibit
hcv
ec
serum
adjust
ec
importantli
much
difficult
develop
resist
alisporivir
vitro
compar
inhibitor
viral
target
delang
et
al
li
et
al
compound
initi
develop
phase
trial
patient
includ
coinfect
hcv
treat
mg
alisporivir
bid
day
rna
decreas
log
surprisingli
much
profound
reduct
hcv
rna
log
alisporivir
treat
patient
vs
log
placebo
group
first
demonstr
clinic
efficaci
hcv
patient
cyclophilin
inhibitor
alon
flisiak
et
al
frequent
advers
effect
jaundic
patient
includ
discontinu
treatment
associ
revers
hyperbilirubinemia
also
decreas
l
platelet
count
alisporivir
group
compar
decreas
l
placebo
group
subsequ
phase
iia
studi
hcv
patient
receiv
alisporivir
reduc
dose
mg
bid
first
week
qd
three
week
combin
mean
viral
load
reduct
log
achiev
genotyp
patient
effect
even
pronounc
genotyp
patient
log
viral
load
reduct
week
flisiak
et
al
base
result
mg
qd
alisporivir
load
dose
mg
bid
first
week
select
studi
phase
iib
trial
gave
plasma
c
trough
slightli
serum
adjust
ec
compound
genotyp
hcv
patient
treat
alisporivir
placebo
combin
ribavirin
week
flisiak
et
al
overal
patient
receiv
alisporivir
tripl
therapi
week
achiev
sustain
virolog
respons
svr
ie
cure
hcv
infect
compar
ribavirin
efficaci
compar
two
approv
hcv
proteas
inhibitor
rate
viral
breakthrough
much
lower
alisporivirtr
patient
confirm
higher
barrier
resist
anoth
phase
ii
trial
compound
test
difficult
treat
ifn
nonrespond
remark
hcv
becam
undetect
patient
receiv
mg
bid
alisporivir
combin
ribavirin
week
compar
receiv
ribavirin
alon
alberti
et
al
sinc
alisporivir
shown
potent
antivir
activ
genotyp
hcv
patient
phase
ii
trial
also
carri
studi
effect
ifnfre
regimen
first
genotyp
patient
given
alisporivir
mg
qd
alon
mg
qd
combin
ribavirin
week
patient
achiev
rapid
virolog
respons
rvr
ie
log
viral
load
reduct
allow
continu
ifnfre
therapi
anoth
week
wherea
ad
achiev
rvr
end
half
patient
receiv
mg
qd
alisporivir
plu
ribavirin
onethird
receiv
mg
qd
alisporivir
cure
hcv
infect
first
demonstr
hosttarget
antivir
alon
cure
viral
infect
importantli
shown
vitro
patient
much
difficult
develop
resist
hosttarget
cyclophilin
inhibitor
make
ideal
candid
combin
inhibitor
viral
target
ifnfre
allor
regimen
coelmont
et
al
li
et
al
main
sideeffect
associ
alisporivir
treatment
transient
revers
increas
bilirubin
total
daili
dose
mg
mechanist
studi
suggest
due
inhibit
uptak
transport
led
elev
indirect
bilirubin
inhibit
efflux
transport
led
elev
direct
bilirubin
kovac
et
al
importantli
none
associ
increas
alt
ast
hemolysi
date
alisporivir
dose
almost
subject
good
overal
safeti
profil
pivot
phase
iii
studi
initi
earli
studi
combin
alisporivir
ribavirin
genotyp
hcv
patient
howev
unfortun
six
case
sever
pancreat
report
includ
one
death
earli
compound
subsequ
put
clinic
hold
caus
risk
pancreat
assess
note
case
pancreat
occur
tripletherapi
arm
includ
ribavirin
none
report
date
alisporivir
alon
ifnfre
regimen
appear
better
safeti
profil
griffel
et
al
thu
hope
alisporivir
andor
cyclophilin
inhibitor
pursu
combin
hcv
inhibitor
number
cyclophilin
inhibitor
develop
tabl
hopkin
et
al
third
nonimmunosuppress
cyclosporin
analog
demonstr
clinic
efficaci
hcv
patient
hcv
genotyp
patient
receiv
mg
tid
alon
mean
viral
load
reduct
log
day
treatment
hopkin
et
al
interestingli
compound
appear
differ
sideeffect
profil
compar
alisporivir
frequent
report
advers
event
elev
serum
creatinin
phosphokinas
cpk
liver
enzym
altast
report
bilirubin
increas
platelet
decreas
new
cyclosporin
analog
also
shown
much
reduc
inhibit
bilirubin
transport
signific
effect
may
thu
address
liabil
associ
firstgener
cyclophilin
inhibitor
ie
hyperbilirubinemia
drugdrug
interact
jiang
et
al
sawada
anoth
class
cyclophilin
inhibitor
sanglifehrin
moss
et
al
well
seri
smallmolecul
inhibitor
identifi
fragmentbas
screen
also
shown
promis
vitro
activ
ahmedbelkacem
et
al
potenti
advantag
target
host
drug
may
inhibit
multipl
virus
exploit
cellular
pathway
provid
first
hint
cyclophilin
could
play
role
viral
replic
year
ago
luban
et
al
discov
cypa
cypb
directli
bind
gag
polyprotein
cyclophilin
inhibitor
block
interact
subsequ
two
independ
studi
demonstr
cypa
cypb
specif
incorpor
particl
via
contact
prolinerich
domain
gag
prevent
cypagag
interact
either
ad
cyclophilin
inhibitor
introduc
mutat
prolinerich
region
gag
block
cypa
packag
infect
releas
virion
frank
et
al
thali
et
al
hydrophob
pocket
cypa
encompass
isomeras
activ
critic
gag
bind
particl
incorpor
braaten
et
al
recent
work
suggest
cypa
modul
uncoat
capsid
core
deliv
cytosol
target
cell
fusion
viral
cellular
membran
strebel
et
al
ylinen
et
al
capsid
core
uncoat
necessari
step
penetr
viral
genom
nucleu
nondivid
cell
subsequ
integr
viral
genom
host
chromosom
strebel
et
al
ylinen
et
al
sinc
cypa
catalyz
cistran
isomer
prolin
bond
within
capsid
bosco
et
al
one
envis
fold
activ
orchestr
fine
tune
timedepend
manner
disassembl
capsid
core
support
hypothesi
recent
studi
provid
evid
cypa
enhanc
infect
coordin
proper
uncoat
capsid
core
well
viral
genom
integr
target
schaller
et
al
shah
et
al
data
strongli
suggest
cypa
present
cytosol
target
cell
control
choic
nuclear
import
machineri
exploit
anoth
function
cypacapsid
interact
recent
propos
specif
manel
et
al
obtain
sever
line
evid
interact
modul
activ
innat
respons
dendrit
cell
critic
sens
pathogen
subsequ
trigger
host
innat
respons
normal
refractori
infect
howev
resist
infect
bypass
activ
dendrit
cell
matur
antivir
type
interferon
respons
nice
demonstr
modul
innat
respons
reli
interact
newli
synthes
capsid
cypa
subsequ
activ
transcript
interferon
regulatori
factor
cyclophilin
inhibitor
csa
prevent
cypacapsid
interactionmedi
dendrit
cell
activ
find
strongli
suggest
cypacapsid
contact
modul
dendrit
cell
intrins
sensor
import
antivir
immun
respons
antihiv
activ
nonimmunosuppress
cyclosporin
analog
alisporivir
well
character
vitro
billich
et
al
ptak
et
al
daeleman
et
al
moreov
mention
alisporivir
also
show
clinic
efficaci
flisiak
et
al
hivhcv
coinfect
patient
remain
one
difficult
treat
popul
dual
antivir
activ
cyclophilin
inhibitor
present
interest
opportun
treat
viral
infect
one
drug
cypa
first
identifi
core
influenza
virion
shaw
et
al
function
remain
elucid
later
report
cypa
interact
protein
influenza
viru
inhibit
nuclear
transloc
earli
stage
infect
liu
et
al
furthermor
cypa
enhanc
ubiquitinmedi
degrad
inhibit
initi
viral
replic
liu
et
al
interestingli
appear
csa
capabl
inhibit
replic
influenza
viru
cypadepend
independ
pathway
liu
et
al
enhanc
bind
cypa
also
impair
nuclear
export
viral
mrna
absenc
cypa
importantli
nonimmunosuppress
cyclosporin
analog
meil
csa
ie
show
similar
antivir
effect
rais
possibl
develop
cyclophilin
inhibitor
influenza
bouchard
et
al
report
csa
inhibit
hbv
replic
block
mitochondri
transit
pore
calcium
signal
shown
recent
cypa
interact
hbv
surfac
antigen
hbsag
promot
secret
vitro
patient
tian
et
al
interestingli
sirna
specif
target
cypa
inhibit
hbv
replic
also
block
hbsag
secret
vitro
furthermor
cyclophilin
inhibitor
alisporivir
capabl
reduc
hbv
dna
secret
hbsag
phillip
et
al
given
fact
class
specif
antivir
drug
current
avail
hbv
nucleo
ide
polymeras
inhibitor
potent
inhibit
viral
replic
neither
clear
viral
cccdna
induc
seroconvers
major
patient
would
great
interest
develop
drug
novel
mechan
could
lead
better
seroconvers
viral
clearanc
cyclophilin
also
appear
play
import
role
replic
virus
luo
et
al
first
report
cypa
bound
nucleocapsid
protein
sar
coronaviru
recent
shown
cyclophilin
interact
viral
nonstructur
protein
csa
inhibit
replic
multipl
coronavirus
de
wild
et
al
pfefferl
et
al
addit
cyclophilin
may
involv
replic
herp
simplex
viru
vahln
et
al
human
cytomegaloviru
key
et
al
vesicular
stomat
viru
bose
et
al
vaccinia
viru
damaso
keller
human
papillomaviru
bienkowskahaba
et
al
develop
cyclophilin
inhibitor
could
therefor
potenti
benefit
treatment
mani
differ
viral
infect
discoveri
develop
cyclophilin
inhibitor
exemplifi
opportun
challeng
pursu
hosttarget
antivir
advantag
high
barrier
resist
broad
genotyp
coverag
acceler
develop
path
known
inhibitor
even
possibl
broadspectrum
antivir
demonstr
cyclophilin
inhibitor
interestingli
toxic
sideeffect
profil
inhibitor
investig
date
differ
one
anoth
preclin
studi
patient
seem
relat
individu
compound
target
challeng
remain
better
understand
mechan
action
toxic
one
could
argu
situat
differ
develop
inhibitor
viral
target
chanc
success
necessarili
lower
either
consid
number
viral
target
inhibitor
pursu
fail
regard
discoveri
novel
host
target
impact
limit
cell
cultur
anim
model
overlook
lesson
learn
previou
failur
translat
vitro
find
clinic
efficaci
statin
impdh
inhibitor
nevertheless
given
right
approach
right
target
block
virushost
interact
could
highli
effect
strategi
treat
viral
infect
mechan
action
cyclophilin
inhibitor
hcv
replic
cyclophilin
cypa
bind
directli
protein
hcv
substrat
cypa
ppias
requir
format
function
viral
replic
complex
cyclophilin
inhibitor
alisporivir
inhibit
cypa
ppias
block
interact
thu
inhibit
viral
replic
chemic
structur
cyclophilin
inhibitor
left
right
cyclosporin
csa
two
nonimmunosuppress
analog
alisporivir
arrow
indic
modif
structur
tabl
potenti
advantag
pro
disadvantag
con
host
target
antivir
therapi
high
barrier
resist
potenti
ontarget
toxic
